Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 11/20 | 0.58 |
| ▸ | MAOA | P21397 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 1/20 | 0.58 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.53 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | GRM5 | P41594 | 1/20 | 0.46 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15358409 | 1.00 | KDM1A (0.58) | KDM1AMAOAMAOBCHRNB4CHRNA3 | |
| SCHEMBL1290616 | 1.00 | KDM1A (0.58) | KDM1AMAOAMAOBCHRNB4CHRNA3 | |
| Hydrochloric Acid SCHEMBL1290426 | 0.99 | KDM1A (0.59) | KDM1AMAOAMAOBCHRNB4CHRNA3 | |
| Hydrochloric Acid SCHEMBL15345983 | 0.99 | KDM1A (0.59) | KDM1AMAOAMAOBCHRNB4CHRNA3 | |
| SCHEMBL1290482 | 0.85 | KDM1A (0.61) | KDM1AMAOAMAOBRAB9ANPC1 | |
| SCHEMBL15355699 | 0.85 | KDM1A (0.61) | KDM1AMAOAMAOBRAB9ANPC1 | |
| SCHEMBL1290483 | 0.85 | KDM1A (0.61) | KDM1AMAOAMAOBRAB9ANPC1 | |
| SCHEMBL1290552 | 0.85 | KDM1A (0.58) | KDM1AMAOBGRM5 | |
| SCHEMBL15355661 | 0.85 | KDM1A (0.58) | KDM1AMAOBGRM5 | |
| SCHEMBL1290553 | 0.85 | KDM1A (0.58) | KDM1AMAOBGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160000768-A1 | CYCLOPROPYLAMINE INHIBITORS OF OXIDASES | ORYZON GENOMICS S.A. (ES) | 2016-01-07 | — | — | US | claimed |
| US-9061966-B2 | Cyclopropylamine inhibitors of oxidases | ORYZON GENOMICS S.A. (ES) | 2015-06-23 | — | — | US | claimed |
| US-20130289076-A1 | CYCLOPROPYLAMINE INHIBITORS OF OXIDASES | ORYZON GENOMICS S.A. (ES) | 2013-10-31 | — | — | US | claimed |
| WO-2012045883-A1 | CYCLOPROPYLAMINE INHIBITORS OF OXIDASES | ORYZON GENOMICS S.A. (ES) | 2012-04-12 | — | — | WO | claimed |
| EP-3430015-B1 | METHODS TO DETERMINE KDM1A TARGET ENGAGEMENT AND CHEMOPROBES USEFUL THEREFOR | ORYZON GENOMICS SA (ES) | 2025-08-06 | — | — | EP | disclosed |
| US-12195783-B2 | Methods to determine KDM1A target engagement and chemoprobes useful therefor | ORYZON GENOMICS S.A. (ES) | 2025-01-14 | — | — | US | disclosed |
| US-20220389478-A1 | METHODS TO DETERMINE KDM1A TARGET ENGAGEMENT AND CHEMOPROBES USEFUL THEREFOR | ORYZON GENOMICS SA (ES) | 2022-12-08 | — | — | US | disclosed |
| US-11034991-B2 | Methods to determine KDM1A target engagement and chemoprobes useful therefor | ORYZON GENOMICS S.A. (ES) | 2021-06-15 | — | — | US | disclosed |
| US-20190085372-A1 | METHODS TO DETERMINE KDM1A TARGET ENGAGEMENT AND CHEMOPROBES USEFUL THEREFOR | ORYZON GENOMICS SA (ES) | 2019-03-21 | — | — | US | disclosed |
| EP-3430015-A1 | METHODS TO DETERMINE KDM1A TARGET ENGAGEMENT AND CHEMOPROBES USEFUL THEREFOR | Oryzon Genomics, S.A. (ES) | 2019-01-23 | — | — | EP | disclosed |
| US-20180284095-A1 | BIOMARKERS ASSOCIATED WITH LSD1 INHIBITORS AND USES THEREOF | ORYZON GENOMICS SA (ES) | 2018-10-04 | — | — | US | disclosed |
| EP-3307909-A1 | BIOMARKERS ASSOCIATED WITH LSD1 INHIBITORS AND USES THEREOF | Oryzon Genomics, S.A. (ES) | 2018-04-18 | — | — | EP | disclosed |
| WO-2017158136-A1 | METHODS TO DETERMINE KDM1A TARGET ENGAGEMENT AND CHEMOPROBES USEFUL THEREFOR | ORYZON GENOMICS, S.A. (ES) | 2017-09-21 | — | — | WO | disclosed |
| WO-2017013061-A1 | BIOMARKERS ASSOCIATED WITH LSD1 INHIBITORS AND USES THEREOF | ORYZON GENOMICS, S.A. (ES) | 2017-01-26 | — | — | WO | disclosed |
| WO-2016198649-A1 | BIOMARKERS ASSOCIATED WITH LSD1 INHIBITORS AND USES THEREOF | ORYZON GENOMICS, S.A. (ES) | 2016-12-15 | — | — | WO | disclosed |
| US-20160000768-A1 | CYCLOPROPYLAMINE INHIBITORS OF OXIDASES | ORYZON GENOMICS S.A. (ES) | 2016-01-07 | — | — | US | disclosed |
| US-9061966-B2 | Cyclopropylamine inhibitors of oxidases | ORYZON GENOMICS S.A. (ES) | 2015-06-23 | — | — | US | disclosed |
| US-20130289076-A1 | CYCLOPROPYLAMINE INHIBITORS OF OXIDASES | ORYZON GENOMICS S.A. (ES) | 2013-10-31 | — | — | US | disclosed |
| WO-2012045883-A1 | CYCLOPROPYLAMINE INHIBITORS OF OXIDASES | ORYZON GENOMICS S.A. (ES) | 2012-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220389478-A1 | METHODS TO DETERMINE KDM1A TARGET ENGAGEMENT AND CHEMOPROBES USEFUL THEREFOR | KDM1B, KDM1A, KDM7A | KDM1A 2/4885MAOA 4155/4885MAOB 3928/4885 |
| US-20180284095-A1 | BIOMARKERS ASSOCIATED WITH LSD1 INHIBITORS AND USES THEREOF | KDM1B, EZH2, DOT1L | KDM1A 5/4885MAOA 526/4885MAOB 410/4885 |
| US-20160000768-A1 | CYCLOPROPYLAMINE INHIBITORS OF OXIDASES | PPOX, MAOB, MAOA | KDM1A 828/4885MAOA 3/4885MAOB 2/4885 |
| US-12195783-B2 | Methods to determine KDM1A target engagement and chemoprobes useful therefor | KDM1B, KDM1A, KDM7A | KDM1A 2/4885MAOA 4155/4885MAOB 3928/4885 |
| US-20190085372-A1 | METHODS TO DETERMINE KDM1A TARGET ENGAGEMENT AND CHEMOPROBES USEFUL THEREFOR | KDM1B, KDM1A, KDM7A | KDM1A 2/4885MAOA 4155/4885MAOB 3928/4885 |
| US-20130289076-A1 | CYCLOPROPYLAMINE INHIBITORS OF OXIDASES | PPOX, MAOB, MAOA | KDM1A 828/4885MAOA 3/4885MAOB 2/4885 |
| US-11034991-B2 | Methods to determine KDM1A target engagement and chemoprobes useful therefor | KDM1B, KDM1A, KDM7A | KDM1A 2/4885MAOA 4155/4885MAOB 3928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.